Production (Stage)
Harvard Bioscience, Inc.
HBIO
$0.2843
-$0.089-23.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.17% | -12.78% | -13.38% | -19.69% | -18.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.17% | -12.78% | -13.38% | -19.69% | -18.23% |
| Cost of Revenue | -1.54% | -8.74% | -13.45% | -18.26% | -16.24% |
| Gross Profit | -17.52% | -15.57% | -13.32% | -20.72% | -19.48% |
| SG&A Expenses | -14.42% | -10.82% | -8.49% | -3.90% | -3.61% |
| Depreciation & Amortization | -12.98% | -9.37% | -1.98% | -4.18% | -3.96% |
| Other Operating Expenses | -82.30% | -- | -- | -- | -- |
| Total Operating Expenses | -12.66% | -11.64% | -10.01% | -11.42% | -5.08% |
| Operating Income | 28.74% | -48.02% | -81.67% | -310.18% | -230.30% |
| Income Before Tax | -1,032.78% | 153.49% | -699.11% | -56.34% | -471.50% |
| Income Tax Expenses | -316.19% | -20.00% | -54.06% | 68.43% | -64.10% |
| Earnings from Continuing Operations | -972.43% | 100.99% | -287.57% | -198.67% | -854.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -972.43% | 100.99% | -287.57% | -198.67% | -854.66% |
| EBIT | 28.74% | -48.02% | -81.67% | -310.18% | -230.30% |
| EBITDA | 106.22% | -16.58% | -85.82% | -94.91% | -114.35% |
| EPS Basic | -955.08% | 100.94% | -279.66% | -191.34% | -831.08% |
| Normalized Basic EPS | 14.66% | 644.68% | -653.66% | -33.87% | -480.83% |
| EPS Diluted | -937.82% | 100.94% | -267.00% | -203.03% | -1,200.00% |
| Normalized Diluted EPS | 14.66% | 629.79% | -653.66% | -33.87% | -487.29% |
| Average Basic Shares Outstanding | 1.60% | 2.22% | 2.17% | 2.67% | 3.05% |
| Average Diluted Shares Outstanding | 1.60% | 4.08% | 2.17% | 2.67% | 1.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |